BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (NASDAQ:BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, c ...

BOSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq: BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/bioa. What is this all about? Shares of BioAge Labs, Inc. were down 73% on December 9, after the company discontinued its STRIDES Phase 2 trial for azelaprag, ...

Core Viewpoint - BioArctic AB has entered into a global exclusive license agreement with Bristol Myers Squibb for its PyroGlutamate-amyloid-beta antibody program, which includes significant financial terms and the potential for future collaboration in neuroscience treatments [1][2]. Group 1: Agreement Details - The agreement grants Bristol Myers Squibb exclusive rights for the development and commercialization of BAN1503 and BAN2803 globally, with BioArctic receiving an upfront payment of USD 100 million and up to USD 1.25 billion in milestone payments [1][2]. - BioArctic will also receive tiered low double-digit royalties on global product sales and retains an option to co-commercialize the products in the Nordic region [2]. Group 2: Technology Overview - BioArctic's PyroGlu-Aβ antibody program targets a specific truncated form of amyloid-beta, which is associated with Alzheimer's disease and leads to harmful aggregates affecting cognitive function [3]. - The BrainTransporter technology, included in BAN2803, aims to enhance the delivery of biotherapeutics across the blood-brain barrier by utilizing the transferrin receptor, potentially improving drug efficacy and safety [4][8]. Group 3: Company Background - BioArctic is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including the development of Leqembi, the first drug shown to slow Alzheimer's progression [9]. - The company has a diverse research portfolio targeting various neurodegenerative conditions, leveraging its proprietary BrainTransporter technology for enhanced treatment delivery [9].

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company devel ...

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ:BIOA). The investigation concerns whether BioAge and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for its lead product candidate, azelapr ...

SAN FRANCISCO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- On December 9, 2024, just months after conducting an initial public offering in September 2024, BioAge Labs, Inc. (NASDAQ: BIOA) made the startling announcement that it was discontinuing a Phase 2 study for its lead product, azelaprag, intended to treat metabolic diseases such as obesity. Hagens Berman has opened an investigation and urges investors in BioAge who purchased shares in the company’s IPO or on the open market and suffered substantial losses to su ...

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc. Why is BioAge being Investigated? BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therap ...

ATLANTA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) complied with federal securities laws. On December 6, 2024, BioAge announced the discontinuation of the Strides Phase 2 study of its investigational drug candidate azelaprag due to safety concerns “after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.”  Following this news, the price of the Company ...

Company Overview - BioAge Labs is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging [3] - The company's lead product candidate, azelaprag, is an orally available small molecule agonist of APJ, which has shown potential in promoting metabolism and preventing muscle atrophy during bed rest in a Phase 1b clinical trial [3] - BioAge initiated a Phase 2 trial of azelaprag in combination with tirzepatide for treating obesity in older adults in mid-2024 [3] Product Development - Azelaprag has potential as an oral regimen to enhance weight loss and improve body composition in patients undergoing obesity therapy with incretin drugs [3] - The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors aimed at treating diseases driven by neuroinflammation [3] - BioAge's preclinical programs leverage insights from its discovery platform based on human longevity data to address key pathways in metabolic aging [3] Upcoming Events - BioAge Labs will present at the Goldman Sachs Second Annual "Year-Ahead" Catalyst Clinic on December 19, 2024, from 11 AM to 12 PM EST [1] - A live webcast of the presentation will be available, with replays accessible in the investor section of the company's website for 30 days following the event [2]

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a comp ...